Literature DB >> 29491130

Acquired thrombotic thrombocytopenic purpura in a child: rituximab to prevent relapse. A pediatric report and literature review.

Sabrina Mariani1, Silvia M Trisolini2, Saveria Capria2, Maria L Moleti2, Marta Chisini3, Giancarlo Ferrazza4, Mahnaz Shafii Bafti4, Maria A Limongiello2, Eleonora Miulli2, Flora Peyvandi3, Robin Foà2, Anna M Testi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29491130      PMCID： PMC5830388          DOI： 10.3324/haematol.2017.185363

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: a pediatric report and literature review.

Authors:  Jérôme Harambat; Delphine Lamireau; Yahsou Delmas; Anne Ryman; Brigitte Llanas; Olivier Brissaud
Journal:  Pediatr Crit Care Med       Date:  2011-03       Impact factor: 3.624

2.  [Paediatric case report of an acquired autoimmune thrombotic thrombocytopenic purpura].

Authors:  C Curtillet; P Poullin; E Doré; C Fossat; P Lefevre; G Michel
Journal:  Arch Pediatr       Date:  2006-09-28       Impact factor: 1.180

3.  Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Evaren E Page; Johanna A Kremer Hovinga; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Blood       Date:  2016-09-13       Impact factor: 22.113

4.  Long-term remission of recurrent thrombotic thrombocytopenic purpura (TTP) after Rituximab in children and young adults.

Authors:  Ivonne Wieland; Karim Kentouche; Madlen Jentzsch; Daniela Lothschütz; Norbert Graf; Karl-Walter Sykora
Journal:  Pediatr Blood Cancer       Date:  2015-01-13       Impact factor: 3.167

5.  Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura.

Authors:  Miguel Hie; Julie Gay; Lionel Galicier; François Provôt; Claire Presne; Pascale Poullin; Guy Bonmarchand; Alain Wynckel; Ygal Benhamou; Philippe Vanhille; Aude Servais; Dominique Bordessoule; Jean-Philippe Coindre; Mohamed Hamidou; Jean-Paul Vernant; Agnès Veyradier; Paul Coppo
Journal:  Blood       Date:  2014-05-28       Impact factor: 22.113

6.  Successful treatment of relapsing autoimmune thrombotic thrombocytopenic purpura with rituximab.

Authors:  Senthilkumar Sankararaman; Majed Jeroudi; Hassan Ibrahim
Journal:  Pediatr Int       Date:  2014-12       Impact factor: 1.524

7.  Rituximab therapy to prevent relapse in chronic relapsing thrombotic thrombocytopenic purpura (TTP) in a child.

Authors:  Somasundaram Jayabose; Julie Dunbar; Theodore S Nowicki; Oya Tugal; Mehmet Fevzi Ozkaynak; Claudio Sandoval
Journal:  Pediatr Hematol Oncol       Date:  2010-05-14       Impact factor: 1.969

8.  Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.

Authors:  Bérangère S Joly; Alain Stepanian; Thierry Leblanc; David Hajage; Hervé Chambost; Jérôme Harambat; Fanny Fouyssac; Vincent Guigonis; Guy Leverger; Tim Ulinski; Thérésa Kwon; Chantal Loirat; Paul Coppo; Agnès Veyradier
Journal:  Lancet Haematol       Date:  2016-10-03       Impact factor: 18.959

9.  Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features.

Authors:  Jessica A Reese; Darrshini S Muthurajah; Johanna A Kremer Hovinga; Sara K Vesely; Deirdra R Terrell; James N George
Journal:  Pediatr Blood Cancer       Date:  2013-06-01       Impact factor: 3.167

10.  Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.

Authors:  Marie Scully; Beverley J Hunt; Sylvia Benjamin; Ri Liesner; Peter Rose; Flora Peyvandi; Betty Cheung; Samuel J Machin
Journal:  Br J Haematol       Date:  2012-05-25       Impact factor: 6.998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.